Keywords: Chorea; neurodegeneration with brain iron accumulation; neuroacanthocytosis
Citation: Walker R. Update on the non-Huntington's disease choreas with comments on the current nomenclature. Tremor Other Hyperkinet Mov 2012; 2: http://tremorjournal.org/article/view/49
*To whom correspondence should be addressed. E-mail: firstname.lastname@example.org
Editor: Elan D. Louis, Columbia University, United States of America
Received: June 29, 2011 Accepted: August 8, 2011 Published: January 30, 2012
Copyright: © 2012 Walker. This is an open-access article distributed under the terms of the Creative Commons Attribution–Noncommercial–No Derivatives License, which permits the user to copy, distribute, and transmit the work provided that the original author(s) and source are credited; that no commercial use is made of the work; and that the work is not altered or transformed.
Competing Interests: The author reports no conflict of interest.
Chorea can be caused by a multitude of etiologies: neurodegenerative, pharmacological, structural, metabolic, and others. This article focuses upon recent developments in the field. I also discuss the nomenclature of these disorders, which has become somewhat unwieldy, but may ultimately be refined by association with the causative gene. This article is not intended to provide an exhaustive review of all causes of chorea, as this is available elsewhere.1,2
The identification in 1993 of the causative trinucleotide repeat expansion within the gene responsible for Huntington's disease (HD)3 was the starting point for the recognition that there were other genetic causes of chorea. Prior to this, any patient with a progressive movement disorder and neuropsychiatric changes was given the diagnosis of HD, particularly if there was a positive family history. However, between 1%4 and 12–15%5,6 of patients thought to have HD were found to be negative for the HD mutation. The identification of the HD gene led to the search for other genes that could cause familial basal ganglia neurodegenerative syndromes. In addition, it became possible to make the diagnosis of HD in those with atypical features, such as late age of onset and the absence of a family history, who had previously been given the now-obsolete label of “senile chorea.”
The grammatically clumsy naming, involving an adjectival construct masquerading as a noun, of the Huntington's disease-like (HDL) disorders, commenced in 1998 with HDL1.7 Although traditional requirements for being “HDL” should have been autosomal dominant (AD) inheritance, in addition to comprising a progressive hyperkinetic movement disorder and cognitive impairment, one of the four disorders with this unfortunate name demonstrated autosomal recessive inheritance (HDL3).
The term HDL1 was used to describe a family with a disorder characterized by personality changes starting in early–mid adulthood, followed by chorea, rigidity, dysarthria, myoclonus, and ataxia, and seizures.7 Symptoms developed in three generations, demonstrating AD inheritance. This disease was determined to be a prion disorder due to an octapeptide repeat.8 Other families with this mutation have a different phenotype in which psychiatric features predominated over a variety of cerebellar, pyramidal or parkinsonian signs.9
HDL2 was reported initially as being due to a CAG repeat expansion, with AD inheritance and clinical features very similar to HD, in one family.10 The mutation was subsequently identified as being a CTG/CAG trinucleotide repeat expansion located within a variably spliced exon, labeled 2A, between exon 1 and exon 2B of junctophilin-3 (JPH3) on chromosome 16q24.3.11 Unusually, neurodegeneration appears to be due to transcription of the antisense CAG repeat.12 In addition, mRNA toxicity, in common with myotonic dystrophy 1 and some of the spinocerebellar ataxias (SCAs),13 may play a significant role in pathogenesis.12 Intriguingly, the latter feature may be shared with HD, and may offer insights into a common disease mechanism.
Only reported to date in subjects of black African ancestry, HDL2 has been found in many countries,5,10,11,14–16 especially among black South Africans. Ten percent may have acanthocytes, resulting in the inclusion of this disorder with neuroacanthocytosis syndromes.17
The term HDL3 was given to five affected siblings with chorea, dystonia, dysarthria, cognitive impairment, and seizures.18 Neuroimaging showed cortical and caudate nucleus atrophy. Although linkage localized the mutation to the vicinity of the HD gene, HD was excluded. No further cases have been reported with this disorder, nor has a causative gene been identified.
HDL4 was the term given to what transpired to be a familial phenotypic variation of SCA17:19 1% of a cohort of non-HD patients were found to have this mutation.5 Although ataxia is a more typical presentation of SCA17, in some families there may be striking phenotypic homogeneity.20
Fortunately, no new disorders have been given an “HDL” name. In addition to being inelegant, the absence of the noun in the term, which most logically would be the repetitive “disease” (“Huntington's disease-like disease 2”), makes the name challenging to translate into other languages such as French or German, where the ending of the adjective should agree with the gender of the noun.
It is this author's hope that this terminology will be abandoned and the named HDL disorders given names related to their causative mutation. One option would be to follow the convention of the neurodegeneration with brain iron accumulation (NBIA) disorders, e.g. “junctophilin 3-associated neurodegeneration (J3AN).” Another alternative would be to adopt terminology similar to that for the neurodegenerative disorders characterized by abnormal protein accumulation, such as “tau-opathy” and “synuclein-opathy,” hence “junctophilin-opathy.” One distinction from these disorders is that in general this terminology has been used to refer to accumulation of the specified protein on neuropathological examination, rather than the causative mutation. Although neither of these options is much more elegant than “HDL,” it is appealing to use nomenclature which is etiologically accurate, and has the additional advantage of not being dependent upon the clinical phenotype which may not be choreiform.
In addition to HDL2 and SCA17, movement disorders can be seen in some of the other SCAs and dentatorubropallidoluysian atrophy (DRPLA). In some cases the typical cerebellar findings, such as abnormalities of eye movement and ataxia, are less prominent than the movement disorder. Parkinsonism, dystonia, and chorea are not infrequent in SCA3 (Machado–Joseph disease), the most common SCA in most populations. Patients with SCA121 and SCA222,23 may occasionally present with or develop chorea. There does not seem to be a relationship between size of the trinucleotide repeat expansion and the phenotype.
DRPLA was initially thought to be seen only in Japanese populations, but has occasionally been reported in Caucasian24,25 or African-American26 families. There are two typical phenotypes related to the age of onset, and thus in this case correlate with the size of the trinucleotide repeat expansion. In younger onset patients myoclonus and seizures are prominent, in addition to ataxia and dementia. In patients with age of onset older than 20 years, chorea and neuropsychiatric symptoms are typical, similar to HD.
The past decade has seen clarification of the clinically and genetically heterogeneous disorders given the term “neuroacanthocytosis.” This term is still often used to refer to cases for which the more accurate term, especially if genetic or protein confirmation has been performed, is chorea-acanthocytosis (ChAc; also referred to as choreoacanthocytosis).
Following the seminal reports by Levine et al.,27 and Critchley et al.,28 in the 1960s, of a neurological disorder accompanied by acanthocytes with normal lipoproteins, the term “neuroacanthocytosis” was adopted, despite the potential for confusion with the disorders of lipoproteins (abetalipoproteinemia [Bassen–Kornzweig disease] and hypobetalipoproteinemia). The term “Levine–Critchley” syndrome was used initially by authors from Japan, where ChAc is more common.29 The widely cited case series published by Hardie et al. in 199130 unfortunately perpetuated diagnostic confusion due to its genetic heterogeneity, but has subsequently been updated.31 It has recently been confirmed that Critchley's original Kentucky kindred were indeed affected by ChAc.32
The identification of mutations in VPS13A (encoding for vacuolar protein sorting-associated protein 13A) as the cause, and the affected protein as chorein,33–35 has facilitated precise diagnosis of ChAc.36 Use of Western blotting to demonstrate absence of the protein has been useful in clinical practice.37 Molecular conformation is challenging due to the large gene size and the many locations and natures of mutations,38 but may be made easier with recent advances in genetic techniques.
As both acanthocytes39–41 and chorea may be variable or absent at any point in a patient's clinical course, it has been suggested that the name “chorea-acanthocytosis” is inaccurate. As the affected protein has been named “chorein,” a more appropriate term may be “chorein disease,” “chorein-associated neurodegeneration,” or “chorein-opathy,” although I am reluctant to advocate for yet another change in nomenclature for a disorder whose taxonomy has already resulted in confusion.
Recognition of an association of the McLeod blood type42,43 with various movement disorders, including chorea, parkinsonism, tics, and dystonia, has permitted molecular diagnosis of this X-linked neuroacanthocytosis syndrome (McLeod syndrome; MLS).44–46 Although very rare, with fewer than a hundred published cases,47 this diagnosis is important because of the potential complications of blood transfusion incompatibility and preventable cardiac complications.44,48
Potential diagnostic confusion may be caused by the observations of acanthocytes in HDL217 and in pantothenate kinase-associated neurodegeneration (PKAN).49 Indeed, one of Hardie's original series was likely to have had this disorder (initially given the name hypoprebetalipoproteinemia, acanthocytosis, retinitis pigmentosa and pallidal degeneration [HARP]50).
The mechanism for the production of acanthocytes is not known. In PKAN, it is likely that this is a result of impaired lipid synthesis; however, this hypothesis raises the question as to why acanthocytosis is not a universal finding in these patients.
This group of disorders is characterized by the finding on magnetic resonance imaging (MRI) of iron deposition primarily in the globus pallidus. Prior to the advent of MRI, the diagnosis was made only post mortem, on the basis of neuropathological findings. The disorders were described as “Hallervorden–Spatz disease” or “Hallervorden–Spatz syndrome” if atypical. Causative mutations in the PANK2 gene were discovered,51 and the term “pantothenate kinase-associated neurodegeneration” was proposed in light of the unethical nature of the work of Drs. Hallervorden and Spatz in Nazi Germany.52,53 The prototypical NBIA disorder, PKAN, typically presents in childhood with dystonia, rather than chorea, in addition to other findings such as pigmentary retinal degeneration.49 The disorder initially termed HARP was found to be allelic with PKAN.50,54
Adult onset of basal ganglia iron deposition is associated with chorea. A small number of families have been reported with autosomal dominant inheritance of mutations of ferritin light chain, responsible for iron transportation, resulting in neuroferritinopathy.55–58 Autosomal recessive inheritance of mutations of ceruloplasmin,59,60 a ferroxidase, results in chorea and dystonia, often orofacial, with the addition of ataxia. Symptomatic heteroplasmic carriers have been reported.61 The pattern of basal ganglia iron deposition can be distinguished in the different disorders by distinctive patterns of iron and inflammation on neuroimaging.62
Childhood-onset NBIA disorders appear to be characterized by dystonia and parkinsonism, and include one phenotype of neuroaxonal dystrophy, due to mutations of PLA2G6 (phospholipase-associated neurodegeneration; PLAN),63–65 Kufor–Rakeb syndrome (PARK9; ATP13A2 mutations),66 and fatty acid hydroxylase-associated neurodegeneration (FAHN),67 and a growing list of other disorders.
Benign hereditary chorea is so called as it does not appear to be associated with a dementing process or severe neurological impairment. It has been associated with mutation of thyroid transcription factor 1 (TITF-1),68–70 also known as NKX2.1. However, this mutation is not found in all families, and the disorder appears to be genetically71 and possibly phenotypically72 heterogeneous. Onset may be in childhood, and there is sometimes also mild ataxia. The chorea may respond to l-dopa.73 Neuropathological findings are subtle and reflect alterations in a subset of striatal interneurons.74 Subtle changes are reported on structural and functional neuroimaging.75,76
Mutations of the same gene have been reported to cause a multisystem disorder comprising congenital hypothyroidism, hypotonia, and pulmonary problems, in addition to chorea.70,77–79 Differences in the size and nature of mutations may account for the varying severity in these two disorders.
An expanding number of paraneoplastic neurologic syndromes have been recognized. Although much less common than cerebellar and neuromuscular presentations, chorea has been reported in renal, small cell lung, breast, Hodgkin's and non-Hodgkin's lymphoma,80–84 due to anti-CRMP-5/CV283,85 or, occasionally, anti-Hu84 or anti-Yo86 neuronal autoantibodies.
Although not technically choreiform in nature, the identification of the anti-N-methyl-D-aspartate (NMDA)-receptor antibody-related syndrome is mentioned here due to its apparent frequency and recent insights into its course and pathogenesis.87–91 This disorder results in encephalopathy with complex, often stereotypic movements with components of dystonia and chorea. In some patients ovarian teratomas are identified, although in others the etiology remains obscure.87 Importantly, some patients may recover after a prolonged disease course.
Prion disease both inherited and sporadic may cause chorea,92 rather than the more typical movement disorder presentation of myoclonus in a patient with progressive cognitive deterioration. In addition to HDL18 (discussed above), new variant Creutzfeldt–Jakob disease, related to bovine spongiform encephalopathy, can cause chorea and cognitive impairment which progress subacutely over months.93,94
Neurosurgical advances for other movement disorders appear to have benefited patients with the non-HD choreas, although at present it is challenging to accurately gauge success rates as cases with poor outcomes are less likely to be reported. There is a need to collate all cases receiving surgery for each of these rare diseases in order to provide general recommendations.
Case reports and small series have reported the effects of deep brain stimulation (DBS) or lesioning of the subthalamic nucleus (STN) or globus palldus pars interna (GPi) in patients with chorea of various etiologies. Case reports of DBS of the GPi in “senile chorea”95 have been promising, although in ChAc96–98 and MLS99 results are mixed. The benefits in these progressive disorders may be limited by ongoing neurodegeneration. The motor thalamus has also been proposed as a potentially promising site for DBS in “senile chorea”95 and has been reported as being beneficial in a patient with ChAc.96,99 The optimal site and frequency of stimulation for treatment of chorea remain to be identified.99 Positive results following pallidotomy have been reported in DRPLA100 and ChAc.101
The most significant advance in medical therapies in the USA has been the recent approval of tetrabenazine,102,103 which depletes monoamines from presynaptic terminals.104 However, the side effects of depression, parkinsonism, and impaired swallowing may be limiting,105 and tetrabenazine should be used with care. Reserpine may also be useful with the same caveats.
As in HD, the newer atypical antipsychotics, including clozapine, quetiapine, aripiprazole, and ziprasidone have been a useful addition to the pharmacological armamentarium. Although parkinsonism and tardive dyskinesia can occasionally be seen with these agents, and sedation can be a significant problem, weight gain is rarely an issue in patients with neurodegenerative choreas, and thus these medications can be helpful.
Other agents with different mechanisms of action have been reported to give benefit in non-HD choreas, including levetiracetam,106 possibly related to a membrane-stabilizing effect. However, caution should be employed, as some anticonvulsants, such as lamotrigine, have been reported to worsen involuntary movements in ChAc.107 Glutamatergic NMDA-receptor antagonists such as amantadine and riluzole may reduce chorea in HD108–112 and may be considered in non-HD choreas.
Although limited by the rarity and clinical heterogeneity of these disorders, quantitative neuroimaging has resulted in demonstration of specific features in some of the non-HD choreas, such as specific atrophy affecting the head of caudate nucleus in ChAc113–115 and progression of neurodegeneration in MLS44,116
Studies of metabolism such as magnetic resonance spectroscopy are in their infancy, but may ultimately lead to additional insights into disease pathogenesis.117
Despite recent advances with progress in molecular medicine, a significant number of subjects with chorea remains undiagnosed. The rarity of many of these disorders means that funding for research is limited, especially in the current climate. There is a need for an internationally accessible database of clinical descriptions, neuroimaging findings, other laboratory features, and tissue samples for all non-diagnosed subjects with chorea, with or without family history. This could be modeled upon the neuroacanthocytosis database (http://www.euro-hd.net/html/na/submodule/), which has been piggy-backed onto the European Huntington's disease database (http://euro-hd.net), with the addition of a centralized tissue bank. Such a resource could be used, for example, for genetic studies, for screening for serological and neuroimaging biomarkers, for searches for distinguishing phenotypic features, and would be a rewarding use of the technology now at our disposal.
Thanks to Benedikt Bader, MD, and Elizabeth Friedmann, PhD, for discussions of grammar and nomenclature.
1. Walker RH. Differential diagnosis of chorea. Curr Neurol Neurosci Rep 2011;11:385–395, http://dx.doi.org/10.1007/s11910-011-0202-2.
2. Walker RH. The differential diagnosis of chorea. 2011. Oxford University Press, New York, NY
3. Huntington Study Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993;72:971–983, http://dx.doi.org/10.1016/0092-8674(93)90585-E.
4. Andrew SE, Goldberg YP, Kremer B, et al. Huntington disease without cag expansion - phenocopies or errors in assignment. Am J Hum Genet 1994;54:852–863.
5. Stevanin G, Fujigasaki H, Lebre AS, et al. Huntington's disease-like phenotype due to trinucleotide repeat expansions in the TBP and JPH3 genes. Brain 2003;126:1599–1603, http://dx.doi.org/10.1093/brain/awg155.
6. Vuillaume I, Meynieu P, Schraen-Maschke S, et al. Absence of unidentified CAG repeat expansion in patients with Huntington's disease-like phenotype. J Neurol Neurosurg Psychiatry 2000;68:672–675, http://dx.doi.org/10.1136/jnnp.68.5.672.
7. Xiang F, Almqvist EW, Huq M, et al. A Huntington disease-like neurodegenerative disorder maps to chromosome 20p. Am J Hum Genet 1998;63:1431–1438.
8. Moore RC, Xiang F, Monaghan J, et al. Huntington disease phenocopy is a familial prion disease. Am J Hum Genet 2001;69:1385–1388.
9. Laplanche JL, Hachimi KH, Durieux I, et al. Prominent psychiatric features and early onset in an inherited prion disease with a new insertional mutation in the prion protein gene. Brain 1999;122:2375–2386, http://dx.doi.org/10.1093/brain/122.12.2375.
10. Margolis RL, O'Hearn E, Rosenblatt A, et al. A disorder similar to Huntington's disease is associated with a novel CAG repeat expansion. Ann Neurol 2001;50:373–380.
11. Holmes SE, O'Hearn E, Rosenblatt A, et al. A repeat expansion in the gene encoding junctophilin-3 is associated with Huntington disease-like 2. Nat Genet 2001;29:377–378, http://dx.doi.org/10.1038/ng760.
12. Wilburn B, Rudnicki DD, Zhao J, et al. An antisense CAG repeat transcript at JPH3 locus mediates expanded polyglutamine protein toxicity in Huntington's disease-like 2 mice. Neuron 2011;70:427–440, http://dx.doi.org/10.1016/j.neuron.2011.03.021.
13. Rudnicki DD, Holmes SE, Lin MW, et al. Huntington's disease-like 2 is associated with CUG repeat-containing RNA foci. Ann Neurol 2007;61:272–282, http://dx.doi.org/10.1002/ana.21081.
14. Rodrigues GG, Walker RH, Brice A, et al. Huntington's disease-like 2 in Brazil—Report of 4 patients. Mov Disord 2008;23:2244–2247, http://dx.doi.org/10.1002/mds.22223.
15. Santos C, Wanderley H, Vedolin L, et al. Huntington disease-like 2: the first patient with apparent European ancestry. Clin Genet 2008;73:480–485, http://dx.doi.org/10.1111/j.1399-0004.2008.00981.x.
16. Magazi DS, Krause A, Bonev V, et al. Huntington's disease: genetic heterogeneity in black African patients. S Afr Med J 2008;98:200–203.
17. Walker RH, Rasmussen A, Rudnicki D. et al. Huntington's Disease-like 2 can present as chorea-acanthocytosis. Neurology 2003;61:1002–1004.
18. Kambouris M, Bohlega S, Al Tahan A, et al. Localization of the gene for a novel autosomal recessive neurodegenerative Huntington-like disorder to 4p15.3. Am J Hum Genet 2000;66:445–452.
19. Richfield EK, Vonsattel JP, Macdonald ME, et al. Selective loss of striatal preprotachykinin neurons in a phenocopy of Huntington's disease. Mov Disord 2002;17:327–332, http://dx.doi.org/10.1002/mds.10032.
20. Schneider SA, van de Warrenburg BP, Hughes TD, et al. Phenotypic homogeneity of the Huntington disease-like presentation in a SCA17 family. Neurology 2006;67:1701–1703, http://dx.doi.org/10.1212/01.wnl.0000242740.01273.00.
21. Namekawa M, Takiyama Y, Ando Y, et al. Choreiform movements in spinocerebellar ataxia type 1. J Neurol Sci 2001;187:103–106, http://dx.doi.org/10.1016/S0022-510X(01)00527-5.
22. Geschwind DH, Perlman S, Figueroa CP, et al. The prevalence and wide clinical spectrum of the spinocerebellar ataxia type 2 trinucleotide repeat in patients with autosomal dominant cerebellar ataxia. Am J Hum Genet 1997;60:842–850.
23. Rottnek M, Riggio S, Byne W, et al. Schizophrenia in a patient with spinocerebellar ataxia 2: coincidence of two disorders or a neurodegenerative disease presenting with psychosis? Am J Psychiatry 2008;165:964–967.
24. Le B, I, Camuzat A, Castelnovo G, et al. Prevalence of dentatorubral-pallidoluysian atrophy in a large series of white patients with cerebellar ataxia. Arch Neurol 2003;60:1097–1099, http://dx.doi.org/10.1001/archneur.60.8.1097.
25. Wardle M, Majounie E, Williams NM, et al. Dentatorubral pallidoluysian atrophy in South Wales. J Neurol Neurosurg Psychiatry 2008;79:804–807, http://dx.doi.org/10.1136/jnnp.2007.128074.
26. Burke JR, Wingfield MS, Lewis KE, et al. The Haw River Syndrome: Dentatorubropallidoluysian atrophy (DRPLA) in an African-American family. Nat Genet 1994;7:521–524, http://dx.doi.org/10.1038/ng0894-521.
27. Levine IM, Estes JW, Looney JM. Hereditary neurological disease with acanthocytosis. A new syndrome. Arch Neurol 1968;19:403–409, http://dx.doi.org/10.1001/archneur.1968.00480040069007.
28. Critchley EM, Clark DB, Wikler A. Acanthocytosis and neurological disorder without betalipoproteinemia. Arch Neurol 1968;18:134–140, http://dx.doi.org/10.1001/archneur.1968.00470320036004.
29. Hirose H. Neuroacanthocytosis in Japan—Review of the literature and cases. in Neuroacanthocytosis Syndromes II, ed. Walker RH, Saiki S, Danek A, Springer-Verlag, Berlin Heidelberg, 2008;75–84.
30. Hardie RJ, Pullon HW, Harding AE, et al. Neuroacanthocytosis. A clinical, haematological and pathological study of 19 cases. Brain 1991;114:13–49.
31. Gandhi S, Hardie RJ, and Lees AJ. An update on the Hardie neuroacanthocytosis series. in Neuroacanthocytosis Syndromes II, ed. Walker RH, Saiki S, Danek A, Springer-Verlag, Berlin Heidelberg, Germany, 2008;43–51.
32. Velayos-Baeza A, Holinski-Feder E, Nietzel B, et al. Chorea-acanthocytosis genotype in Critchley's original Kentucky neuroacanthocytosis kindred. Arch Neurol 2011;68:1330–1333, http://dx.doi.org/10.1001/archneurol.2011.239.
33. Ueno S, Maruki Y, Nakamura M, et al. The gene encoding a newly discovered protein, chorein, is mutated in chorea-acanthocytosis. Nat Genet 2001;28:121–122, http://dx.doi.org/10.1038/88825.
34. Rampoldi L, Dobson-Stone C, Rubio JP, et al. A conserved sorting-associated protein is mutant in chorea-acanthocytosis. Nat Genet 2001;28:119–120, http://dx.doi.org/10.1038/88821.
35. Velayos-Baeza A, Vettori A, Copley RR, et al. Analysis of the human VPS13 gene family. Genomics 2004;84:536–549, http://dx.doi.org/10.1016/j.ygeno.2004.04.012.
36. Rampoldi L, Danek A, Monaco AP. Clinical features and molecular bases of neuroacanthocytosis. J Mol Med 2002;80:475–491.
37. Dobson-Stone C, Velayos-Baeza A, Filippone LA et al. Chorein detection for the diagnosis of chorea-acanthocytosis. Ann Neurol 2004;56:299–302, http://dx.doi.org/10.1002/ana.20200.
38. Dobson-Stone C, Danek A, Rampoldi L, et al. Mutational spectrum of the CHAC gene in patients with chorea-acanthocytosis. Eur J Hum Genet 2002;10:773–781.
39. Sorrentino G, De Renzo A, Miniello S, et al. Late appearance of acanthocytes during the course of chorea-acanthocytosis. J Neurol Sci 1999;163:175–178, http://dx.doi.org/10.1016/S0022-510X(99)00005-2.
40. Bayreuther C, Borg M. Chorea-acanthocytosis: a diagnosis not to be ruled out in absence of acanthocytes. J Neurol 2008;255:98.
41. Malandrini A, Fabrizi GM, Palmeri S, et al. Choreo-acanthocytosis like phenotype without acanthocytes: clinicopathological case report. A contribution to the knowledge of the functional pathology of the caudate nucleus. Acta Neuropathol (Berl) 1993;86:651–658, http://dx.doi.org/10.1007/BF00294306.
42. Symmans WA, Shepherd CS, Marsh WL, et al. Hereditary acanthocytosis associated with the McLeod phenotype of the Kell blood group system. Br J Haematol 1979;42:575–583.
43. Redman CM, Russo D, Lee S. Kell, Kx and the McLeod syndrome. Baillieres Best Pract Res Clin Haematol 1999;12:621–635, http://dx.doi.org/10.1053/beha.1999.0045.
44. Danek A, Rubio JP, Rampoldi L, et al. McLeod neuroacanthocytosis: genotype and phenotype. Ann Neurol 2001;50:755–764, http://dx.doi.org/10.1002/ana.10035.
45. Jung HH, Hergersberg M, Kneifel S, et al. McLeod syndrome: a novel mutation, predominant psychiatric manifestations, and distinct striatal imaging findings. Ann Neurol 2001;49:384–392, http://dx.doi.org/10.1002/ana.76.
46. Danek A, Tison F, Rubio J, et al. The chorea of McLeod syndrome. Mov Disord 2001;16:882–889, http://dx.doi.org/10.1002/mds.1188.
47. Walker RH, Danek A, Uttner I, et al. McLeod phenotype without the McLeod syndrome. Transfusion 2006;47:299–305, http://dx.doi.org/10.1111/j.1537-2995.2007.01106.x.
48. Oechslin E, Kaup D, Jenni R, et al. Cardiac abnormalities in McLeod syndrome. Int J Cardiol 2009;132:130–132.
49. Hayflick SJ, Westaway SK, Levinson B, et al. Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N Engl J Med 2003;348:33–40.
50. Orrell RW, Amrolia PJ, Heald A. et al. Acanthocytosis, retinitis pigmentosa, and pallidal degeneration: a report of three patients, including the second reported case with hypoprebetalipoproteinemia (HARP syndrome). Neurology 1995;45:487–492.
51. Zhou B, Westaway SK, Levinson B, et al. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 2001;28:345–349, http://dx.doi.org/10.1038/ng572.
52. Shevell MI, Peiffer J. Julius Hallervorden's wartime activities: implications for science under dictatorship. Pediatr Neurol 2001;25:162–165, http://dx.doi.org/10.1016/S0887-8994(00)00243-5.
53. Shevell M. Hallervorden and history. N Engl J Med 2003;348:3–4.
54. Malandrini A, Cesaretti S, Mulinari M, et al. Acanthocytosis, retinitis pigmentosa, pallidal degeneration. Report of two cases without serum lipid abnormalities. J Neurol Sci 1996;140:129–131, http://dx.doi.org/10.1016/0022-510X(96)00155-4.
55. Curtis AR, Fey C, Morris CM, et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet 2001;28:350–354, http://dx.doi.org/10.1038/ng571.
56. Crompton DE, Chinnery PF, Bates D, et al. Spectrum of movement disorders in neuroferritinopathy. Mov Disord 2004;20:95–99, http://dx.doi.org/10.1002/mds.20284.
57. Mir P, Edwards MJ, Curtis AR, et al. Adult-onset generalized dystonia due to a mutation in the neuroferritinopathy gene. Mov Disord 2004;20:243–245, http://dx.doi.org/10.1002/mds.20280.
58. Kubota A, Hida A, Ichikawa Y, et al. A novel ferritin light chain gene mutation in a Japanese family with neuroferritinopathy: description of clinical features and implications for genotype-phenotype correlations. Mov Disord 2009;24:441–445, http://dx.doi.org/10.1002/mds.22435.
59. Xu X, Pin S, Gathinji M, et al. Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis. Ann N Y Acad Sci 2004;1012:299–305, http://dx.doi.org/10.1196/annals.1306.024.
60. Miyajima H. Aceruloplasminemia, an iron metabolic disorder. Neuropathology 2003;23:345–350, http://dx.doi.org/10.1046/j.1440-1789.2003.00521.x.
61. McNeill A, Pandolfo M, Kuhn J, et al. The neurological presentation of ceruloplasmin gene mutations. Eur Neurol 2008;60:200–205, http://dx.doi.org/10.1159/000148691.
62. McNeill A, Birchall D, Hayflick SJ, et al. T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. Neurology 2008;70:1614–1619, http://dx.doi.org/10.1212/01.wnl.0000310985.40011.d6.
63. Morgan NV, Westaway SK, Morton JE, et al. PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat Genet 2006;38:752–754, http://dx.doi.org/10.1038/ng1826.
64. Gregory A, Westaway SK, Holm IE, et al. Neurodegeneration associated with genetic defects in phospholipase A(2). Neurology 2008;71:1402–1409, http://dx.doi.org/10.1212/01.wnl.0000327094.67726.28.
65. Mubaidin A, Roberts E, Hampshire D, et al. Karak syndrome: a novel degenerative disorder of the basal ganglia and cerebellum. J Med Genet 2003;40:543–546, http://dx.doi.org/10.1136/jmg.40.7.543.
66. Schneider SA, Paisan-Ruiz C, Quinn NP, et al. ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. Mov Disord 2010;25:979–984, http://dx.doi.org/10.1002/mds.22947.
67. Kruer MC, Paisan-Ruiz C, Boddaert N, et al. Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA). Ann Neurol 2010;68:611–618, http://dx.doi.org/10.1002/ana.22122.
68. Breedveld GJ, van Dongen JW, Danesino C. et al. Mutations in TITF-1 are associated with benign hereditary chorea. Hum Mol Genet 2002;11:971–979, http://dx.doi.org/10.1093/hmg/11.8.971.
69. Mahajnah M, Inbar D, Steinmetz A. et al. Benign hereditary chorea: clinical, neuroimaging, and genetic findings. J Child Neurol 2007;22:1231–1234, http://dx.doi.org/10.1177/0883073807306261.
70. Devos D, Vuillaume I, De Becdelievre A. et al. New syndromic form of benign hereditary chorea is associated with a deletion of TITF-1 and PAX-9 contiguous genes. Mov Disord 2006;21:2237–2240, http://dx.doi.org/10.1002/mds.21135.
71. Bauer P, Kreuz FR, Burk K, et al. Mutations in TITF1 are not relevant to sporadic and familial chorea of unknown cause. Mov Disord 2006;21:1734–1737, http://dx.doi.org/10.1002/mds.21031.
72. Schrag A, Quinn NP, Bhatia KP et al. Benign hereditary chorea—Entity or syndrome? Mov Disord 2000;15:280–288, http://dx.doi.org/10.1002/1531-8257(200003)15:2<280::AID-MDS1011>3.0.CO;2-Q.
73. Asmus F, Horber V, Pohlenz J, et al. A novel TITF-1 mutation causes benign hereditary chorea with response to levodopa. Neurology 2005;64:1952–1954, http://dx.doi.org/10.1212/01.WNL.0000164000.75046.CC.
74. Kleiner-Fisman G, Calingasan NY, Putt M, et al. Alterations of striatal neurons in benign hereditary chorea. Mov Disord 2005;20:1353–1357, http://dx.doi.org/10.1002/mds.20577.
75. Maccabelli G, Pichiecchio A, Guala A, et al. Advanced magnetic resonance imaging in benign hereditary chorea: study of two familial cases. Mov Disord 2010;25:2670–2674, http://dx.doi.org/10.1002/mds.23281.
76. Salvatore E, Di Maio L, Filla A, et al. Benign hereditary chorea: clinical and neuroimaging features in an Italian family. Mov Disord 2010;25:1491–1496, http://dx.doi.org/10.1002/mds.23065.
77. Krude H, Schutz B, Biebermann H, et al. Choreoathetosis, hypothyroidism, and pulmonary alterations due to human NKX2-1 haploinsufficiency. J Clin Invest 2002;109:475–480.
78. Ferrara AM, De Michele G, Salvatore E. et al. A novel NKX2.1 mutation in a family with hypothyroidism and benign hereditary chorea. Thyroid 2008;18:1005–1009, http://dx.doi.org/10.1089/thy.2008.0085.
79. Willemsen MA, Breedveld GJ, Wouda S, et al. Brain-thyroid-lung syndrome: a patient with a severe multi-system disorder due to a de novo mutation in the thyroid transcription factor 1 gene. Eur J Pediatr 2005;164:28–30.
80. Kujawa KA, Niemi VR, Tomasi MA, et al. Ballistic-choreic movements as the presenting feature of renal cancer. Arch Neurol 2001;58:1133–1135, http://dx.doi.org/10.1001/archneur.58.7.1133.
81. Tani T, Piao Y, Mori S, et al. Chorea resulting from paraneoplastic striatal encephalitis. J Neurol Neurosurg Psychiatry 2000;69:512–515, http://dx.doi.org/10.1136/jnnp.69.4.512.
82. Batchelor TT, Platten M, Palmer-Toy DE, et al. Chorea as a paraneoplastic complication of Hodgkin's disease. J Neurooncol 1998;36:185–190, http://dx.doi.org/10.1023/A:1005860103173.
83. Vernino S, Tuite P, Adler CH, et al. Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma. Ann Neurol 2002;51:625–630, http://dx.doi.org/10.1002/ana.10178.
84. Dorban S, Gille M, Kessler R, et al. [Chorea-athetosis in the anti-Hu syndrome]. Rev Neurol (Paris) 2004;160:126–129, http://dx.doi.org/10.1016/S0035-3787(04)70863-2.
85. Honnorat J, Cartalat-Carel S, Ricard D, et al. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry 2009;80:412–416, http://dx.doi.org/10.1136/jnnp.2007.138016.
86. Krolak-Salmon P, Androdias G, Meyronet D, et al. Slow evolution of cerebellar degeneration and chorea in a man with anti-Yo antibodies. Eur J Neurol 2006;13:307–308.
87. Luca N, Daengsuwan T, Dalmau J, et al. Anti-N-methyl-D-aspartate receptor encephalitis: A newly recognized inflammatory brain disease in children. Arthritis Rheum 2011;63:2515–2522, http://dx.doi.org/10.1002/art.30437.
88. Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011;10:63–74, http://dx.doi.org/10.1016/S1474-4422(10)70253-2.
89. Hughes EG, Peng X, Gleichman AJ, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 2010;30:5866–5875, http://dx.doi.org/10.1523/JNEUROSCI.0167-10.2010.
90. Vincent A, Bien CG. Anti-NMDA-receptor encephalitis: a cause of psychiatric, seizure, and movement disorders in young adults. Lancet Neurol 2008;7:1074–1075, http://dx.doi.org/10.1016/S1474-4422(08)70225-4.
91. Dalmau J, Tuzun E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007;61:25–36, http://dx.doi.org/10.1002/ana.21050.
92. Lahiri N, Mead S, Tabrizi SJ. Chorea in the prion diseases. in The differential diagnosis of chorea, ed. Walker RH, Oxford University Press, New York, 2011;188–205.
93. Bowen J, Mitchell T, Pearce R, et al. Chorea in new variant Creutzfeldt-Jacob disease. Mov Disord 2000;15:1284–1285, http://dx.doi.org/10.1002/1531-8257(200011)15:6<1284::AID-MDS1043>3.0.CO;2-Y.
94. McKee D, Talbot P. Chorea as a presenting feature of variant Creutzfeldt-Jakob disease. Mov Disord 2003;18:837–838, http://dx.doi.org/10.1002/mds.10423.
95. Yianni J, Nandi D, Bradley K, et al. Senile chorea treated by deep brain stimulation: a clinical, neurophysiological and functional imaging study. Mov Disord 2004;19:597–602, http://dx.doi.org/10.1002/mds.10716.
96. Burbaud P, Rougier A, Ferrer X, et al. Improvement of severe trunk spasms by bilateral high-frequency stimulation of the motor thalamus in a patient with chorea-acanthocytosis. Mov Disord 2002;17:204–207, http://dx.doi.org/10.1002/mds.1260.
97. Wihl G, Volkmann J, Allert N, et al. Deep brain stimulation of the internal pallidum did not improve chorea in a patient with neuro-acanthocytosis. Mov Disord 2001;16:572–575, http://dx.doi.org/10.1002/mds.1109.
98. Ruiz PJ, Ayerbe J, Bader B, et al. Deep brain stimulation in chorea acanthocytosis. Mov Disord 2009;24:1546–1547, http://dx.doi.org/10.1002/mds.22592.
99. Burbaud P. Deep brain stimulation in neuroacanthocytosis. Mov Disord 2005;20:1681–1682.
100. Watarai M, Hashimoto T, Yamamoto K, et al. Pallidotomy for severe generalized chorea of juvenile-onset dentatorubral-pallidoluysian atrophy. Neurology 2003;61:1452–1454.
101. Fujimoto Y, Isozaki E, Yokochi F, et al. [A case of chorea-acanthocytosis successfully treated with posteroventral pallidotomy]. Rinsho Shinkeigaku 1997;37:891–894.
102. Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 1988;38:391–394.
103. Chatterjee A, Frucht SJ. Tetrabenazine in the treatment of severe pediatric chorea. Mov Disord 2003;18:703–706, http://dx.doi.org/10.1002/mds.10427.
104. Pearson SJ, Reynolds GP. Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington's disease. Neuropharmacology 1988;27:717–719, http://dx.doi.org/10.1016/0028-3908(88)90080-9.
105. Moss JH, Stewart DE. Iatrogenic parkinsonism in Huntington's chorea. Can J Psychiatry 1986;31:865–866.
106. Lin FC, Wei LJ, Shih PY. Effect of levetiracetam on truncal tic in neuroacanthocytosis. Acta Neurol Taiwan 2006;15:38–42.
107. Al-Asmi A, Jansen AC, Badhwar A, et al. Familial temporal lobe epilepsy as a presenting feature of choreoacanthocytosis. Epilepsia 2005;46:1256–1263, http://dx.doi.org/10.1111/j.1528-1167.2005.65804.x.
108. Lucetti C, Del Dotto P, Gambaccini G, et al. IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study. Neurology 2003;60:1995–1997.
109. Verhagen ML, Morris MJ, Farmer C, et al. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology 2002;59:694–699.
110. O'suilleabhain P, Dewey RB, Jr. A randomized trial of amantadine in Huntington disease. Arch Neurol 2003;60:996–998, http://dx.doi.org/10.1001/archneur.60.7.996.
111. Rosas HD, Koroshetz WJ, Jenkins BG, et al. Riluzole therapy in Huntington's disease (HD). Mov Disord 1999;14:326–330, http://dx.doi.org/10.1002/1531-8257(199903)14:2<326::AID-MDS1019>3.0.CO;2-Q.
112. Seppi K, Mueller J, Bodner T, et al. Riluzole in Huntington's disease (HD): an open label study with one year follow up. J Neurol 2001;248:866–869.
113. Henkel K, Danek A, Grafman J, et al. Head of the caudate nucleus is most vulnerable in chorea-acanthocytosis: a voxel-based morphometry study. Mov Disord 2006;21:1728–1731, http://dx.doi.org/10.1002/mds.21046.
114. Huppertz HJ, Kroll-Seger J, Danek A, et al. Automatic striatal volumetry allows for identification of patients with chorea-acanthocytosis at single subject level. J Neural Transm 2008;115:1393–1400, http://dx.doi.org/10.1007/s00702-008-0094-8.
115. Walterfang M, Looi JC, Styner M, et al. Shape alterations in the striatum in chorea-acanthocytosis. Psychiatry Res 2011;192:29–36, http://dx.doi.org/10.1016/j.pscychresns.2010.10.006.
116. Valko PO, Hanggi J, Meyer M. et al. Evolution of striatal degeneration in McLeod syndrome. Eur J Neurol 2010;17:612–618.
117. Ismailogullari S, Caglayan AO, Bader B. et al. Magnetic resonance spectroscopy in two siblings with chorea-acanthocytosis. Mov Disord 2010;25:2894–2897, http://dx.doi.org/10.1002/mds.23365.